Keywords: Bayer, rivaroxaban, research, European Society of Cardiology

Bayer completes Ph II rivaroxaban study enrollment

Article | 01 September 2009

Print This

German drug major Bayer Schering Pharma revealed at the European Society of Cardiology Congress in Barcelona, Spain, that it has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in